Report: Medicare Part D Pays Needlessly High Brand-Name Drug Prices Compared with Other Developed Countries and with U.S. Government Programs

View the report.

View the letter to Congress.

View press release.

Because of congressional restrictions on the government’s ability to negotiate with the pharmaceutical industry, Medicare Part D drug prices are significantly higher than those in either Medicaid or the Veterans Health Administration and 30 other countries, a study by Carleton University and Public Citizen finds.